All In Biotech

Drug Trial Radar · NCT06434961

The Trial of SHR6508 in Secondary Hyperparathyroidism

A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 498 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

498

Actual

Start

Jun 14, 2024

Primary completion

Sep 29, 2025

Study completion Nov 11, 2025

Sponsor

Sponsor type
Industry
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

Conditions

  • Secondary Hyperparathyroidism

Interventions

  • SHR6508 plus oral placebo tabletsDrug

    SHR6508 plus oral placebo tablets

  • Cinacalcet plus intravenous placeboDrug

    Cinacalcet plus intravenous placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants to End of Study whose iPTH decreased by>30% from baselineTime frame: efficacy assessment period, defined as Week 20-27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.